This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Chronic disease treatment

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Management of chronic disease:

  • conservative for mild or moderate disease
  • valve surgery - repair, valvotomy or replacement in severe disease
  • warfarin anticoagulation for mitral stenosis and mitral regurgitation if there is atrial fibrillation or dilated left atrium - larger than 5 cm on echo
  • diuretic if required
  • digoxin in atrial fibrillation
  • antibiotic prophylaxis to prevent endocarditis

Note that surgery must be undertaken before the left ventricle dilates to an end systolic dimension of 5.5cm or more. If this has occurred then there is a reduction in prospects for recovery of left ventricular function.

Vasodilator therapy in aortic regurgitation:

  • vasodilator therapy (including hydralazine, calcium-channel blockers, and angiotensin-converting enzyme inhibitors) has been employed in patients with asymptomatic chronic aortic incompetence
    • a systematic review was undertaken and identified one study (out of 10) that suggested that the use of vasodilators slowed the rate of progression to surgery for aortic valve replacement
    • however the authors concluded that vasodilators inconsistently improve hemodynamic and structural parameters in asymptomatic patients with chronic AI (1)

Reference:

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.